Omega Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Omega Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,000	Closed	-$3.68M	–	86
2018 Q1	$3.68M	Buy	+45,000	New	+$3.48M	0.14%	63

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Omega Advisors's AGIO Position: Q2 2018 in Review

Omega Advisors sold out of Agios Pharmaceuticals (AGIO) in Q2 2018, closing a stake of 45,000 shares — an estimated $3.68M sold.

Omega Advisors first reported a position in AGIO in Q1 2018 and held it in 1 quarter. The position peaked at $3.68M in Q1 2018. 217 funds tracked by Wall St. Rank hold AGIO as of Q2 2018.

Omega Advisors reported no remaining Agios Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Omega Advisors sold 45,000 Agios Pharmaceuticals shares in Q2 2018, an estimated $3.68M.
Omega Advisors first reported a position in Agios Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Omega Advisors's Agios Pharmaceuticals position peaked at $3.68M in Q1 2018.
217 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2018.

Based on Omega Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.